Glass House Brands (GLAS) Cash from Operations (2020 - 2026)
Glass House Brands' (GLAS) quarterly Cash from Operations came in at 11755000.0 in Q1 2026, down 575.72% year-on-year from 2471000.0 in Q1 2025, and down 213.63% on a QoQ basis from 3748000.0 in Q4 2025.
Glass House Brands (GLAS) Cash from Operations (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Cash from Operations data on file, last reported at 11755000.0 in Q1 2026.
- On a quarterly basis, Cash from Operations fell 575.72% year-over-year to 11755000.0 in Q1 2026; TTM through Mar 2026 was 2826000.0, a 108.63% decrease from a year earlier, with the FY2025 full-year figure at 11400000.0, down 59.85% from the prior year.
- Cash from Operations for Q1 2026 stood at 11755000.0, down from 3748000.0 in the prior quarter.
- Over the last five years, Cash from Operations for GLAS reached as high as 21783228000000.0 in Q3 2023 and fell as low as 11755000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 2191865866235.29 across 5 years, with a median of 7777000.0 in 2022.
- Across the five-year window, Cash from Operations soared 299631646.91% in 2023 and sank 575.72% in 2026, its largest moves.
- Year by year, Cash from Operations stood at 15478419000000.0 in 2022, then plunged by 100.0% to 1441000.0 in 2023, then surged by 468.49% to 8192000.0 in 2024, then slumped by 145.75% to 3748000.0 in 2025, then tumbled by 213.63% to 11755000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 11755000.0 in Q1 2026, 3748000.0 in Q4 2025, and 5060000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 463.30 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | -11.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.76 Mn |
| Mar 31, 2026 | -11.76 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Sep 30, 2025 | -5.06 Mn |
| Sep 30, 2025 | -5.06 Mn |
| Jun 30, 2025 | 17.74 Mn |
| Jun 30, 2025 | 17.74 Mn |
| Mar 31, 2025 | 2.47 Mn |
| Mar 31, 2025 | 2.47 Mn |
| Dec 31, 2024 | 8.19 Mn |
| Dec 31, 2024 | 8.19 Mn |
| Sep 30, 2024 | 13.18 Mn |
| Sep 30, 2024 | 13.18 Mn |
| Jun 30, 2024 | 8.90 Mn |
| Jun 30, 2024 | 8.90 Mn |
| Mar 31, 2024 | -1.88 Mn |
| Mar 31, 2024 | -1.88 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Dec 31, 2023 | 1.44 Mn |